ReviewTrends in immunology2022
Memory B cell diversity: insights for optimized vaccine design.
Review in Trends in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination.European journal of immunology · 2026Article
- The multilayered identity of B cell memory.Cellular & molecular immunology · 2026Review
- Artificial intelligence in bioinformatics: a survey.Briefings in bioinformatics · 2025Review
- Malaria: past, present, and future.Signal transduction and targeted therapy · 2025Review
- Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection.Cell reports · 2025Article
- B-cell depletion limits HTLV-1-infected T-cell expansion and ameliorate HTLV-1-associated myelopathy.Annals of clinical and translational neurology · 2024Observational
- Atypical and non-classical CD45RBNature communications · 2024Article
- Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.Vaccine · 2024Article
- Memory B cells.Nature reviews. Immunology · 2024Review
- Immune imprinting and next-generation coronavirus vaccines.Nature microbiology · 2023Review
- Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2.Nature communications · 2023Article
- CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes.Science advances · 2023Article
- A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.Vaccine · 2023Review
- Extracellular Vesicle-Based SARS-CoV-2 Vaccine.Vaccines · 2023Review
- Humoral immunity for durable control of SARS-CoV-2 and its variants.Inflammation and regeneration · 2023Review
- Decreased antibody response to influenza vaccine with an enhanced antibody response to subsequent SARS-CoV-2 vaccination in patients with chronic hepatitis B virus infection.Immunity, inflammation and disease · 2023Article
- B-Cell Responses to Sars-Cov-2 mRNA Vaccines.Pathogens & immunity · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The overarching logos of mammalian memory B cells (MBCs) is to cache the potential for enhanced antibody production upon secondary exposure to cognate antigenic determinants. However, substantial phenotypic diversity has been identified across MBCs, hinting at the existence of unique origins or subfunctions within this compartment. Herein, we discuss recent advancements in human circulatory MBC subphenotyping as driven by high-throughput cell surface marker analysis and other approaches, as well as speculated and substantiated subfunctions. With this in mind, we hypothesize that the relative induction of specific circulatory MBC subsets might be used as a biomarker for optimally durable vaccines and inform vaccination strategies to subvert antigenic imprinting in the context of highly mutable pathogens such as influenza virus or SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.